Clinical Trial · NCT05987098

BBPA PET/CT in Patients With Malignant Tumors

Overview

This study is an open-labeled phase II diagnostic clinical trial to explore the safety and clinical value of BBPA-PET/CT in suspected malignant tumor patients. The investigation regarding the clinical value of BBPA concerning the metabolic characteristics of BBPA in suspected malignant tumors. Quantitative features will be extracted to analysis the PET images. For patient who took surgery after multiple examination, histopathology, molecular pathology and LAT-1 immunohistochemistry will also be obtained.

Sponsor

Peking Union Medical College Hospital

Phase

N/A

ClinicalTrials.gov

NCT05987098

Drug / Compound

BBPA

Isotope(s):

Target(s):

LAT1/LAT2

Ligand Class: Small Molecules

Eligibility

Inclusion

Meet the indications for PET examination, show a clear indication and no contraindications;
Have a performance status of score ≥80 on KPS scale or score 0-1 points on ECOG scale, a relatively good general situation;

Exclusion

Unable to adhere strictly to protocol requirements.
Does not meet the PET-CT scan sedation requirements, or there are contraindications for PET-CT examination;
Have a history of imaging agent allergies;